Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Total Non-Current Liabilities (2017 - 2025)

Crinetics Pharmaceuticals has reported Total Non-Current Liabilities over the past 5 years, most recently at $130.9 million for Q4 2025.

  • For Q4 2025, Total Non-Current Liabilities rose 20.17% year-over-year to $130.9 million; the TTM value through Dec 2025 reached $130.9 million, up 20.17%, while the annual FY2025 figure was $130.9 million, 20.17% up from the prior year.
  • Total Non-Current Liabilities for Q4 2025 was $130.9 million at Crinetics Pharmaceuticals, up from $121.0 million in the prior quarter.
  • Over five years, Total Non-Current Liabilities peaked at $130.9 million in Q4 2025 and troughed at $96.2 million in Q4 2023.
  • A 3-year average of $110.9 million and a median of $107.3 million in 2024 define the central range for Total Non-Current Liabilities.
  • On a YoY basis, Total Non-Current Liabilities climbed as much as 20.17% in 2025 and fell as far as 10.66% in 2025.
  • Year by year, Total Non-Current Liabilities stood at $96.2 million in 2023, then increased by 13.21% to $109.0 million in 2024, then increased by 20.17% to $130.9 million in 2025.
  • Business Quant data shows Total Non-Current Liabilities for CRNX at $130.9 million in Q4 2025, $121.0 million in Q3 2025, and $115.7 million in Q2 2025.